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BACKGROUND: Advances in the treatment of metastatic colorectal cancer (mCRC) in the last decade have significantly improved
survival; however, simple biomarkers to predict response or toxicity have not been identified, which are applicable to all community
oncology settings worldwide. The use of inflammatory markers based on differential white-cell counts, such as the neutrophil/
lymphocyte ratio (NLR), may be simple and readily available biomarkers.
METHODS: Clinical information and baseline laboratory parameters were available for 349 patients, from two independent cohorts,
with unresectable mCRC receiving first-line palliative chemotherapy. Associations between baseline prognostic variables, including
inflammatory markers such as the NLR and tumour response, progression and survival were investigated.
RESULTS: In the training cohort, combination-agent chemotherapy (P¼0.001) and NLRp5( P¼0.003) were associated with
improved clinical benefit. The ECOG performance status X1( P¼0.002), NLR45( P¼0.01), hypoalbuminaemia (P¼0.03) and
single-agent chemotherapy (Po0.0001) were associated with increased risk of progression. The ECOG performance status X1
(P¼0.004) and NLR45( P¼0.002) predicted worse overall survival (OS). The NLR was confirmed to independently predict OS in
the validation cohort (Po0.0001). Normalisation of the NLR after one cycle of chemotherapy in a subset of patients resulted in
improved progression-free survival (P¼0.012).
CONCLUSION: These results have highlighted NLR as a potentially useful clinical biomarker of systemic inflammatory response in
predicting clinically meaningful outcomes in two independent cohorts. Results of this study have also confirmed the importance of a
chronic systemic inflammatory response influencing clinical outcomes in patients with mCRC.
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Colorectal cancer (CRC) is the third leading cause of worldwide
cancer mortality after lung and stomach cancer and is responsible
for 639000 deaths or 1.1% of total deaths (World Health
Organisation, 2004). There have been major advances in the
treatment of metastatic CRC (mCRC) in the last 10–15 years,
involving the introduction of new cytotoxic and molecular targeted
therapies. However, use of these newer treatments result in
increased toxicities and are prohibitively expensive. Hence, there is
a need for accurate predictors of outcomes from treatment, in
particular, in identifying those patients who are more likely to
benefit by being assisted in rationalising increasingly expensive
treatments, especially in under-resourced communities.
Tumour development and growth occurs as a result of
interactions among the tumour, host-derived stromal tissues
including blood vessels and host immune/inflammatory cells (see
Figure 1), with chronic inflammation having an important role in
cancer development and progression (Balkwill and Mantovani,
2010; Coussens and Werb, 2002). Lymphocytic infiltration in
primary colorectal tumour tissue with different lymphocyte
subpopulations has been investigated as potential prognostic
factors (Page `s et al, 2005; Galon et al, 2006). This chronic
inflammatory state also has effects on normal tissues, including the
liver, resulting in an ongoing release of ‘acute-phase proteins’ that
may be used to monitor this process. Current prognostication in
advanced CRC, as in other malignancies, involves a poorly defined
combination of clinical experience with the use of relatively crude
and subjective covariates, such as performance status, with few
markers in clinical practice apart from the use of k-ras mutation
status and treatment with epidermal growth-factor receptor
inhibitors (Bokemeyer et al, 2009; Koopman et al, 2009; Van
Cutsem et al, 2009; Chua et al, 2010).
Over the last 10 years, laboratory markers of a systemic
inflammatory response, including plasma C-reactive protein
concentration (CRP), hypoalbuminaemia and Glasgow Prognostic
Score (GPS, which combines CRP and albumin), and absolute
white cell or its components (neutrophils, neutrophil/lymphocyte
ratios (NLRs) and platelet/lymphocyte ratios (PLRs)) have been
investigated as prognostic and predictive markers in different
cancer populations, with the best evidence for their use demon-
strated in surgical patients with CRC (Roxburgh and McMillan,
2010). Emerging evidence suggests that elevated baseline levels of
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sCRP (Hilmy et al, 2005; Crumley et al, 2006a; Mitsuru et al, 2009;
Johnson et al, 2010), abnormal GPS scores (Forrest et al, 2003;
Crumley et al, 2006b; McMillan, 2009) and elevated NLR
(Yamanaka et al, 2007; Halazun et al, 2008, 2009; Liu et al, 2010)
or PLR (Smith et al, 2009) are not only negatively correlated with
outcome after surgical resection but also in those with inoperable
cancers. These inflammation scores based on readily available and
inexpensive tests could potentially be ideal biomarkers of outcome
in patients with mCRC.
Evidence for the use of these inflammatory markers as direct
predictors of outcome in patients with advanced malignancy
receiving first-line chemotherapy is lacking. Two recent studies
have highlighted the use of the systemic inflammatory response in
predicting survival (Teramukai et al, 2009) and toxicity (Arieta
et al, 2010) in patients receiving chemotherapy for advanced non-
small-cell lung cancer. Neutrophilia has been shown to be an
adverse prognostic factor in patients receiving first-line oxalipla-
tin-based chemotherapy for CRC (Michael et al, 2006). An elevated
NLR in CRC patients with liver-only colorectal metastases
receiving neoadjuvant chemotherapy before surgical resection of
liver metastases predicted worse survival (Kishi et al, 2009). In
addition, those patients in whom NLR normalised after chemo-
therapy had significantly improved 1-, 3- and 5-year survival
similar to patients with NLRp5 at baseline. These data suggest
that NLR may be a readily available and useful biomarker for
monitoring early response and prognosis with chemotherapy for
CRC (Kishi et al, 2009). The aims of the current study were to
investigate (1) NLR in predicting treatment response, toxicity and
survival in medical patients receiving first-line chemotherapy for
advanced CRC in a training set; (2) validating the results from the
training cohort in a separate community patient cohort; and (3)
assessing the impact of normalisation of NLR for monitoring early
response during chemotherapy.
PATIENTS AND METHODS
Study population
In total, there were 349 patients with available clinical information
and baseline laboratory parameters. The training set consisted of
171 patients enrolled in first-line chemotherapy trials at the
Sydney Cancer Centre for advanced CRC between 1999 and 2007.
The independent validation set included 178 patients from a
community-based clinical database in the province of Alberta and
included patients referred to medial oncology units at the Cross
Cancer Institute who received first-line chemotherapy for
advanced CRC between 2004 and 2007 (Prado et al, 2008). Table 1
lists the comparative baseline clinical information and laboratory
parameters for both cohorts before chemotherapy commencement.
Methods
Baseline clinical information and biochemical evaluation, includ-
ing full blood count (neutrophils, lymphocytes, haemoglobin and
platelets) and albumin before chemotherapy commencement, were
collected in a database for patients in both the training and
validation sets. Alkaline phosphatase was also collected in the
training set. Prognostic variables with 410% missing data were
not included in the analysis. Differential white-cell counts
(neutrophils and lymphocytes) were also collected for patients
before cycle 2 of chemotherapy. Response rates, dates of
progression and survival were available for patients in the training
set; however, only survival data were available for patients in the
validation cohort. Dates of death were followed up by the
investigators through hospital records, local Cancer Registries or
phone contact through patient relatives, local medical practitioners
and palliative-care services. Patients were consented to undergo
analyses before commencing chemotherapy, and the study was
approved by institutional research ethics committees in both
Sydney and Edmonton.
Statistical analysis
Statistical analyses were performed using SPSS Graduate Version
17.0 (IBM Corporation 2010, Somers, NY, USA). Response rates
were determined according to criteria determined by individual
clinical trials, RECIST criteria. Clinical response was defined as
either complete or partial response and non-response as either
stable or progressive disease. Clinical benefit was defined as
complete response, partial response and stable disease and no
benefit as progressive disease alone. Progression-free survival
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Figure 1 The effect of cytokines in the local tumour environment and systemic organs, and the clinical manifestations of these interactions. Red arrows
indicate cytokines being released from either tumour or other organ.
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s(PFS) was defined as the date of commencing protocol treatment
to the date of first progression or death from any cause without
progression. Overall survival (OS) was defined as the date from the
date of commencing protocol treatment to the date of death from
any cause. The w
2-tests were used to test associations between
variables of interest (grouped using standard thresholds) and
clinical response or benefit. Multivariate modelling was used for
calculation of hazard ratios and clinical response and benefit. The
follow-up period commenced at the start of chemotherapy with the
censor date of January 2010. Survival analysis was performed using
the Kaplan–Meier method with log-rank test in univariate
analyses. Cox regression analysis was used for multivariate
survival analysis and for calculation of hazard ratios.
RESULTS
Patient characteristics
Baseline clinical demographics and laboratory values for both
training and validation sets are presented in Table 1. There were
no differences in age and gender between the two cohorts.
However, a significantly higher proportion of patients in the
validation cohort had rectal cancer as the primary tumour site and
had ECOG PSX1. The majority of patients in both cohorts
received combination chemotherapy±a biological agent.
Prognostic variables in training set
Table 2 shows the univariate analyses between prognostic variables
of interest and clinical benefit, PFS and OS in the training set. At
the time of analysis, all patients had progressed on chemotherapy
and 169 patients were deceased. The overall clinical response
(complete response and partial response) was 55% (93 out of 168
evaluable patients) and clinical benefit (complete response, partial
response and stable disease) was 75% (128 out of 168 evaluable
patients). The median PFS was 6.7 months (95% CI 5.6–7.8
months) and OS was 15.3 months (95% CI 12.4–18.2).
Clinical benefit and response Younger age (p65 years old),
ECOG performance status 0, absence of hypoalbuminaemia,
normal alkaline phosphatase, low or normal neutrophil counts
and NLRp5 were associated with improved clinical benefit
(Table 2). Similarly, younger age (p65 years old), ECOG
performance status 0 and NLRp5 were associated with improved
clinical response. In addition, combination-agent chemotherapy
was also associated with improved clinical response.
PFS and OS Variables predicting improved PFS included
younger age, ECOG performance status 0, combination-agent
chemotherapy, single site of metastasis, absence of neutrophilia or
hypoalbuminaemia and NLRp5 (Table 2 and Figure 2A). The
following variables were associated with improved OS: younger
age, ECOG PS 0, combination-agent chemotherapy, absence of
neutrophilia or anaemia. Hypoalbuminaemia, elevated alkaline
phosphatase and NLR45 were also significantly associated with
worse OS (Table 2 and Figure 2B).
Multivariate analysis In multivariate analysis performed in the
training set (Table 3), combination-agent chemotherapy and
NLRp5 were associated with improved clinical benefit. The ECOG
performance status X1, NLR45, hypoalbuminaemia and single-
agent chemotherapy were associated with increased risk of
progression. The ECOG performance status X1 and NLR45
predicted worse OS.
Prognostic variables according to NLR Table 4 summarises
analysis of baseline characteristics and prognostic variables
according to NLR groups. Patients with NLR45 were more likely
to suffer from hypoalbuminaemia (P-level o0.0001) and elevated
alkaline phosphatase (P-level 0.008). The association between NLR
and gender (P-level 0.06) and number of metastatic sites (P-level
0.05) approached statistical significance.
NLR in validation cohort
At the time of analysis, 82% (146 out of 178) of patients were
deceased. The median OS in this cohort was 16.8 months (95% CI
13.1–20.4 months). Independent predictors of survival from the
training cohort (ECOG performance status and NLR) were tested
in the validation cohort. The NLR was statistically significantly
associated with OS (P-level o0.0001). Patients with NLRp5 had
median OS of 19.1 months (95% CI 15.3–22.8) compared with
patients with NLR45 (median OS 11.3 months; 95%CI 8.3–14.3;
Figure 2C). The ECOG performance status was not predictive of
survival in this cohort (median OS for ECOG 0 was 21.5 months
(95% CI 4.1–38.9) and PSX1 15.7 months (95% CI 13.1–18.3;
P-level 0.15)).
Normalisation of NLR pre-cycle 2 and correlation with PFS
and OS (training cohort)
Patients were categorised into the following categories: (1) patients
with NLRp5 at baseline (n¼120; cohort 1), (2) NLR45a t
baseline and before cycle 2 of chemotherapy (n¼21; cohort 2) and
Table 1 Baseline patient characteristics in the training and validation sets
before commencement of chemotherapy
Training set
(n¼171)
No. (%)
Validation set
(n¼178)
No. (%) P-value
Age, median (range) 61 (33–84) 63 (32–85) 0.40
Gender (M/F) 110/61 (64/36) 100/73 (56/44) 0.22
Primary cancer site —
a
Colon 103 (64) 116 (65)
Rectosigmoid 52 (32) 23 (13)
Rectum 4 (3) 39 (22)
Synchronous 2 (1) 0 o0.0001
ECOG performance status
0 85 (50) 30 (17)
1 81 (47) 96 (54)
X2 5 (3) 52 (29) o0.0001
Chemotherapy regimen
Single agent only 43 (25) 34 (19)
Combination
chemotherapy±biologicals
128 (75) 92 (52)
Unknown 0 52 (29) o0.0001
Number of sites
1 91 (53) NA __
41 80 (47)
Baseline levels of prognostic factors
Albumin, median (range), gl
 1 40 (27–48) 39 (20–47)
Carcinoembryonic antigen,
median (range)
38.6 (0.7–945) NA
Haemoglobin, median (range) 127 (82–162) 122 (78–170)
Neutrophils, median (range) 5.5 (1.5–14.8) 5.1 (1.9–21.4)
Lymphocytes, median (range) 1.4 (0.4–4.9) 1.5 (0.2–3.3)
Neutrophil–lymphocyte ratio,
median (range)
3.7 (1.0–30.8) 3.5 (0.9–74.5)
p5 120 (71) 123 (69)
45 49 (29) 55 (31)
Abbreviations: ECOG¼Eastern Cooperative Oncology Group; F¼female;
M¼male; NA¼not available.
aMissing data for 10 patients (training set).
Neutrophil/lymphocyte ratio in advanced colorectal cancer
W Chua et al
1290
British Journal of Cancer (2011) 104(8), 1288–1295 & 2011 Cancer Research UK
M
o
l
e
c
u
l
a
r
D
i
a
g
n
o
s
t
i
c
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2 of chemotherapy (n¼21; cohort 3). Patients with normalisation
of NLR before cycle 2 of chemotherapy (cohort 3) had an improved
PFS of 5.8 months (95% CI 4.1–7.5) compared with patients
without normalisation of NLR pre-cycle 2 (cohort 2; median PFS
3.7 months; 95% CI 0.6–6.8 months; P-level 0.012; Figure 3A).
Normalisation of NLR improved median OS from 9.4 months
(cohort 2; 95% CI 3.2–15.5) to 12.1 months (cohort 3; 95% CI
7.3–16.8) in patients with a persistently elevated NLR, although
this did not reach statistical significance (P-level 0.053; Figure 3B).
Patients with normalised NLR before cycle 2 of chemotherapy
(cohort 3) did not have significantly different median PFS
(5.8 months (95% CI 4.1–7.5) vs 8.0 months (95% CI 6.9–9.0);
P-level 0.37) or OS (12.1 months (95% CI 7.3–16.8) vs 18.3 months
(95% CI 16.2–20.4); P-level 0.77) in comparison with patients
with NLRp5 before chemotherapy commencement (cohort 1;
Figures 3A and B). Normalisation of NLR before cycle 2 of
chemotherapy was not performed in the validation cohort, as there
was 410% of missing data for this patient group.
DISCUSSION
This is the first study, to our knowledge, to describe the use of NLR
in a non-selected unresectable mCRC setting for patients receiving
first-line palliative chemotherapy to provide useful information
regarding prognostication, and the data have been validated in an
independent community-based cohort. These results support the
use of NLR as a marker of systemic inflammatory response and as
an independent predictor of clinical benefit, progression and
survival in patients receiving chemotherapy for mCRC. An NLR
cutoff 45 was able to identify a subset of patients least likely to
respond to chemotherapy (40 vs 16%) and those at higher risk of
progression and death (HR 1.6 and 1.7, respectively). A cutoff
Table 2 Univariate analysis of clinicopathological factors, inflammatory response and response rate, PFS and OS in training set
Clinical benefit PFS OS
Variable
Total
no. (%)
Clinical
benefit (%)
a P-value
Survival (months)
Median (95% CI) P-value
Survival (months)
Median (95 %CI) P-value
Age, years
p65 113 (66) 90 (81) 7.4 (5.8–9.0) 17.5 (14.5–20.8) 0.03
465 58 (34) 38 (67) 0.04 5.5 (4.3–6.7) 0.05 12.1 (10.9–13.3)
Gender
Male 110 (64) 81 (74) 6.1 (4.7–7.6) 15.8 (12.6–19.0) 0.85
Female 61 (36) 47 (80) 0.44 7.3 (5.1–9.5) 0.13 14.6 (10.0–19.2)
ECOG PS
0 85 (50) 69 (84) 9.0 (8.2–9.7) 18.5 (16.1–21.0) 0.003
X1 86 (50) 59 (69) 0.02 4.9 (4.0–5.7) 0.001 11.5 (9.3–13.7)
Primary site
Colon 103 (64) 76 (75) 6.3 (5.1–7.5) 12.9 (10.8–15.1)
Rectosigmoid junction 52 (32) 40 (77) 8.5 (6.9–10.1) 18.3 (16.9–19.8)
Rectum 4 (3) 3 (75) 5.0 (0–12.6) 4.3 (9.0–25.6)
Synchronous 2 (1) 1 (50) 0.86 3.9 (—) 0.21 11.4 (—) 0.51
Chemotherapy
Single 43 (25) 23 (54) 3.9 (2.3–5.5) 11.0 (8.2–13.9)
Combination 128 (75) 105 (84) 0.07 8.0 (6.9–9.1) o0.0001 17.5 (14.5–20.6) 0.01
Number of sites
1 91 (53) 72 (82) 8.4 (7.2–9.6) 17.5 (14.3–20.6)
41 80 (47) 56 (70) 0.07 5.0 (4.0–6.0) 0.06 12.3 (7.4–17.3) 0.18
Neutrophil count
oULN 133 (78) 105 (80) 7.8 (6.7–9.0) 17.4 (15.5–19.4)
XULN 38 (22) 23 (62) 0.02 4.8 (3.4–6.2) 0.02 9.4 (6.6–12.1) 0.004
Haemoglobin
XLLN 79 (46) 61 (77) 7.7 (5.9–9.4) 17.5 (15.5–19.6)
oLLN 92 (54) 67 (78) 0.77 6.0 (4.8–7.2) 0.58 12.7 (10.1–15.4) 0.03
Albumin
4LLN 117 (69) 32 (63) 4.9 (3.9–5.9) 18.3 (16.5–20.1)
pLLN 53 (31) 96 (83) 0.005 8.0 (6.9–9.0) 0.002 10.4 (7.7–13.2) 0.002
Alkaline phosphatase
oULN 96 (56) 77 (82) 8.0 (6.9–9.1) 18.3 (15.6–21.1)
XULN 74 (44) 50 (69) 0.04 5.5 (4.3–6.7) 0.25 11.5 (9.5–13.5) 0.007
NLR
p5 120 (71) 99 (84) 8.0 (6.9–9.0) 18.3 (16.2–20.4)
45 49 (29) 29 (60) 0.001 4.7 (4.1–5.3) 0.005 10.0 (8.6–11.5) 0.009
Abbreviations: CI¼confidence interval; ECOG¼Eastern Cooperative Oncology Group; OS¼overall survival; LLN¼lower limits of normal; NLR¼neutrophil/lymphocyte
ratio; PFS¼progression-free survival; PS¼performance status; ULN¼upper limits of normal.
aMissing data (o10%) for some prognostic variables.
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sscore of 5 was chosen on the basis of previous studies (Halazun
et al, 2008, 2009; Kishi et al, 2009) and this represents a simple
measurement to use in clinical practice, although other cutoffs
have been used (Duffy et al, 2006; Cho et al, 2009). This identifies
B30% of CRC patients with a raised NLR receiving first-line
chemotherapy in both cohorts and associated with shorter survival
of up to 8 months. These results are highly clinically relevant in
this increasingly common malignancy.
In addition, evidence for significantly improved outcomes with
normalisation of NLR after the first cycle is promising for possible
manipulation of the systemic inflammatory response through
targeted anti-inflammatory mediators such as IL-6 blocking
antibodies. If the use of NLR and normalistion of NLR after cycle
1 are confirmed, this would provide additional prognostic
information for clinicians at an earlier time point before conven-
tional staging with computed tomography scans and potentially
identify a proportion of patients in whom further treatment may
be futile. For example, in the training cohort, there was NLR
normalisation after one cycle of chemotherapy in 50% (21 out of
42) of evaluable patients, which resulted in a 2-month PFS
improvement (5.8 vs 3.7 months) compared with patients without
NLR normalisation. These data will permit not only retrospective
evaluations of established large cohorts with known outcome data
to corroborate these findings but also to undertake correlation
with molecular characteristics, such as microsatellite instability
and B-raf mutations, which are associated with worse cancer
outcomes.
The strengths in our training cohort were that patient data were
retrospectively analysed from robust prospectively collected data
through entry into clinical trials. As the patients were eligible for
enrolment in a clinical trial, it is highly unlikely that the elevated
NLR was due to other active inflammatory diseases or infection or
were requiring high doses of steroids; however, these issues should
be specifically assessed in future studies. Other independent
predictive variables identified from the training cohort, such as
performance status, use of combination chemotherapy and
hypoalbuminaemia, have also been reported from previous studies
and strengthens the case for this cohort being representative of a
palliative mCRC population. The median OS in both cohorts (15.3
and 16.8 months in training and validation cohorts, respectively)
are shorter than those reported using modern combination
chemotherapy regimens, which have median OS upwards of 24
months. However, a significant proportion of the patients in both
cohorts received single-agent chemotherapy, with patients enrolled
in chemotherapy trials from as early as 1999. There were also
significant baseline differences in the types of chemotherapy
regimens between the Australian and Canadian cohorts. In the
Canadian cohort, up to 29% of patients did not have the type of
chemotherapy specified, which may account for some of the
survival difference between the two cohorts. The validation cohort
in this study failed to identify performance status as an
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Figure 2 PFS according to NLR in (A) training cohort. OS according to
NLR in B (training) and (C) validation cohorts of patients with mCRC
treated with chemotherapy.
Table 3 Multivariate analysis of prognostic factors of clinical response,
PFS and OS (training set)
Prognostic variable Hazard ratio (95% CI) P-level
Clinical benefit Chemotherapy type
Single agent 1
Combination 4.0 (1.8–9.2) 0.001
NLR
451
p5 3.4 (1.5–7.8) 0.003
PFS ECOG performance status
01
1 or more 1.5 (1.1–2.1) 0.02
NLR
p51
45 1.6 (1.1–2.2) 0.01
Albumin
XLLN 1
oLLN 1.5 (1.0–2.1) 0.03
Chemotherapy type
Combination 1
Single agent 2.8 (1.9–4.0) o0.0001
OS ECOG performance status
01
1 or more 1.6 (1.2–2.2) 0.004
NLR
p51
45 1.7 (1.2–2.5) 0.002
Abbreviations: CI¼confidence interval; ECOG¼Eastern Cooperative Oncology
Group; OS¼overall survival; LLN¼lower limits of normal; NLR¼neutrophil/
lymphocyte ratio; PFS¼progression-free survival.
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sindependent prognosticator, which, although surprising, may reflect
the community-based origins of this group. However, in both
cohorts, the proportion of patients with NLR45 was surprisingly
consistent between the two cohorts (29 and 31%). In spite of
differences between the cohorts, NLR remained an independent
prognosticator and may reflect that it is an even more robust and
accurate prognosticator than performance status alone. The hetero-
geneity of treatment regimens used could be criticised; however, this
is probably more reflective of day-to-day clinical practice.
The NLR is a simple, readily available and robust laboratory
variable. Other authors have advocated the use of GPS or a
modified GPS, based on albumin and CRP levels, and validated its
use as a prognostic variable particularly in the pre-operative
setting. Two studies have reported the use of GPS in patients
receiving chemotherapy for mCRC and gastro-oesophageal malig-
nancies (Crumley et al, 2008; Ishizuka et al, 2009). However, this
assessment is complicated by the requirement for an additional
blood test to measure CRP levels, which may not be readily
available as was in the case of both our training and validation sets.
The NLR, as a continuous variable, may also be a more accurate
and dynamic variable reflecting acute changes in the inflammatory
state of a patient rather than GPS, which is applied as a static,
categorical variable. The NLR and GPS have not been compared in
the same population in CRC patients, and this comparison should
be undertaken to discern whether these two indices are over-
lapping or additive as indicators of cancer-associated inflamma-
tion. In CRC, the use of NLR has previously been confirmed as an
independent prognostic factor in a cohort of patients with liver-
only colorectal metastases, the majority of whom proceeded to
hepatic resection post chemotherapy (Kishi et al, 2009). Although
this is an important subset of patients with mCRC, these patients
would have been highly selected for surgical intervention and not
representative of the majority of patients with mCRC. The findings
in our study are not only consistent with this earlier report but also
supports the use of NLR in a more generalised patient population
receiving first-line chemotherapy both in a clinical trial and
community setting. Although elevated NLR was correlated with the
presence of hypoalbuminaemia and elevated alkaline phosphatase
in this study (Table 4), other prognostic variables, such as
performance status, site or extent of disease, were relatively well-
balanced between the high- and low-NLR groups, suggesting that
NLR provides additional information than these other variables.
The association of both raised NLR and hypoalbuminaemia is
likely because of its role as a marker of systemic inflammation. The
reasons for the correlation between alkaline phosphatase and NLR
are unclear. Alkaline phosphatase may be a more accurate marker
of the extent of liver involvement or indirectly related to systemic
inflammation. The NLR has also been previously shown to
independently predict outcomes in non-malignant disease, such
Table 4 Baseline characteristics according to NLR
Variable NLRp5N L R 45 P-level
Age (median) 61 61 0.32
Gender
Male 72 (60%) 37 (76%)
Female 48 (40%) 12 (24%) 0.06
ECOG performance status
0 69 (58%) 24 (49%)
1 and 2 60 (50%) 25 (51%) 0.90
Number of metastatic sites
1 69 (58%) 20 (41%)
41 51 (42%) 29 (59%) 0.05
Primary site
Colon 70 (62%) 31 (67%)
Rectum and rectosigmoid junction 42 (37%) 14 (30%)
Synchronous 1 (1%) 1 (1%) 0.61
Site of metastases
Liver 96 (80%) 44 (90%) 0.13
Lung 37 (31%) 17 (35%) 0.63
Other 43 (36%) 21 (43%) 0.39
Anaemia
Present 64 (53%) 28 (57%)
Absent 56 (47%) 21 (43%) 0.65
Hypoalbuminaemia
Present 26 (22%) 26 (53%)
Absent 93 (78%) 23 (47%) o0.0001
Alkaline phosphatase levels
oULN 75 (63%) 20 (41%)
XULN 44 (37%) 29 (59%) 0.008
Abbreviations: ECOG¼Eastern Cooperative Oncology Group; NLR¼neutrophil/
lymphocyte ratio; ULN¼upper limits of normal.
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2008) and percutaneous coronary intervention (Duffy et al, 2006)
in which the systemic inflammation response has been implicated
as a major contributing factor. This adds credibility for the use
of NLR as a potential biomarker of the systemic inflammatory
response.
In recent years, there have been significant developments and
discoveries in cancer genomics. The development of gene-
expression-based arrays or examining germline single-nucleotide
polymorphisms for defining prognosis or predicting response to
therapy has limited clinical application even in the two most
common malignancies, lung and breast cancers (Hartman et al,
2010; Subramanian and Simon, 2010). For example, Wacholder
et al (2010) discovered that the inclusion of 10 common breast
cancer genetic variants only modestly improved the performance
of existing risk-assessment models in 411000 patients, with little
change in the predicted breast-cancer risk among most women,
using currently available genetic information. These tests are also
expensive and confined to use in developed countries, with limited
application in under-resourced communities. A useful biomarker
needs to be not only accurate and reproducible but also easily
accessible. The prognostic importance of the systemic reaction to
tumours has been relatively ignored in the quest for tumour-based
molecular assessments of outcome. These data will encourage a
re-evaluation of that approach.
These results have highlighted the use of a potential clinical
biomarker of systemic inflammatory response in predicting
clinically meaningful outcomes in two independent cohorts. In
addition, results of the study have also confirmed the importance
of a chronic systemic inflammatory response influencing clinical
outcomes in patients with mCRC. Validation of these results in
larger patient populations will allow many potential applications in
the treatment of mCRC, a major cause of morbidity worldwide.
Clinical applications include (1) prognostication and in-patient
stratification in clinical trials, (2) as a marker of response to
chemotherapy treatment and, more excitingly, (3) in identifying
patients for possible interventions with anti-inflammatory media-
tors. The results of this study, we believe, strongly support the use
of NLR in these settings, and more importantly, as a dynamic
marker of interactions among tumour, host and the systemic
inflammatory response.
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